Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma

ATRX公司 体内 医学 癌症研究 离体 平滑肌肉瘤 内科学 病理 生物 突变 基因 遗传学
作者
Justin Harold,Stefania Bellone,Diego Manavella,Levent Mutlu,Blair McNamara,Tobias M.P. Hartwich,Margherita Zipponi,Yang Yang-Hartwich,Cem Demirkiran,Miguel Skyler Verzosa,Jungmin Choi,Weilai Dong,Natália Buza,Pei Hui,Gary Altwerger,Gloria S. Huang,Vaagn Andikyan,Mitchell Clark,Elena Ratner,Masoud Azodi,Peter E. Schwartz,Alessandro D. Santin
出处
期刊:Gynecologic Oncology [Elsevier]
卷期号:168: 157-165 被引量:8
标识
DOI:10.1016/j.ygyno.2022.11.014
摘要

Uterine leiomyosarcoma (uLMS) is a rare, highly aggressive malignancy. Recent data suggest 50% of uLMS may harbor alterations in the ATRX gene and such mutations may confer sensitivity to ataxia-telangiectasia-and-Rad3-related (ATR) kinase inhibitors. We sought to investigate the in vivo activity of Elimusertib (BAY1895344), a novel ATR-inhibitor, against ATRX-mutated uLMS patient-derived xenografts (PDXs).Two fully characterized uLMS (i.e., LEY-11 and LEY-16) were grafted into female CB-17/SCID mice. Treatments with control vehicle or BAY1895344 (20 mg/kg dosed twice daily 3 days on 4 days off) were given via oral gavage and tumor measurements as well as weights obtained twice weekly. Tumor volume differences were calculated with a two-way ANOVA. Mechanistic studies were performed ex vivo using BAY1895344 treated uLMS tumor samples by western blot analysis.Both PDX LEY-11 and PDX LEY-16 harboring ATRX gene mutations demonstrated an aggressive behavior in vivo (i.e., control mice were euthanized on average at day 12.5 for PDX LEY-11 and at day 33 for PDX LEY-16). In both tumor models BAY1895344 20 mg/kg dosed with an intermittent oral schedule was able to induce significant growth inhibition compared to vehicle control treatment (p < 0.001 for both LEY-11 and LEY-16) and prolong median overall survival [PDX LEY-11 (12.5 vs. 42 days, p < 0.001) and PDX LEY-16 (33 vs. 60 days, p < 0.001)]. There were not significant changes in weight between treatment and controls. By western blot assays BAY1895344 exposure decreased phosphorylated-ATR and increased expression of apoptotic molecules in LMS PDXs.BAY1895344 demonstrates promising in vivo activity against biologically aggressive PDX models of uLMS harboring ATRX mutations, with no significant toxicity. Clinical trials of BAY1895344 in uLMS patients are warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
Vce April完成签到,获得积分10
6秒前
7秒前
zmsql发布了新的文献求助10
8秒前
10秒前
共享精神应助chem采纳,获得10
10秒前
大模型应助大萝贝采纳,获得10
10秒前
11秒前
隐形曼青应助科研通管家采纳,获得10
11秒前
华仔应助科研通管家采纳,获得100
11秒前
11秒前
斯文败类应助科研通管家采纳,获得10
11秒前
Ysheng完成签到,获得积分10
11秒前
wanci应助科研通管家采纳,获得10
11秒前
李爱国应助科研通管家采纳,获得10
11秒前
情怀应助科研通管家采纳,获得80
11秒前
gjww应助科研通管家采纳,获得10
11秒前
Akim应助科研通管家采纳,获得10
11秒前
天天快乐应助科研通管家采纳,获得10
11秒前
李健应助科研通管家采纳,获得10
11秒前
CodeCraft应助123采纳,获得10
15秒前
19秒前
科研通AI2S应助苹果煎饼采纳,获得10
20秒前
不止夏天发布了新的文献求助10
23秒前
23秒前
24秒前
24秒前
张小鱼完成签到 ,获得积分10
24秒前
Seven应助穿山甲采纳,获得10
25秒前
25秒前
25秒前
负数完成签到,获得积分10
26秒前
123发布了新的文献求助10
29秒前
木子李完成签到,获得积分20
29秒前
doug完成签到,获得积分0
29秒前
谋勇兼备完成签到,获得积分10
32秒前
Dong发布了新的文献求助10
32秒前
36秒前
zmsql完成签到,获得积分10
37秒前
Dong完成签到,获得积分10
37秒前
高分求助中
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
Yuwu Song, Biographical Dictionary of the People's Republic of China 700
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
Sphäroguß als Werkstoff für Behälter zur Beförderung, Zwischen- und Endlagerung radioaktiver Stoffe - Untersuchung zu alternativen Eignungsnachweisen: Zusammenfassender Abschlußbericht 500
少脉山油柑叶的化学成分研究 430
Revolutions 400
Sport in Ancient Times 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2454372
求助须知:如何正确求助?哪些是违规求助? 2126151
关于积分的说明 5414858
捐赠科研通 1854798
什么是DOI,文献DOI怎么找? 922503
版权声明 562340
科研通“疑难数据库(出版商)”最低求助积分说明 493566